{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:10:08Z","timestamp":1791861008755,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102316","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T19:24:19Z","timestamp":1739215459000},"page":"102316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7147-7119","authenticated-orcid":false,"given":"Matthew N.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-7457","authenticated-orcid":false,"given":"Oluwafolajimi","family":"Adesanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-4824","authenticated-orcid":false,"given":"Vince E.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-407X","authenticated-orcid":false,"given":"Ryan M.","family":"Antar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-072X","authenticated-orcid":false,"given":"Michael J.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102316_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.clgc.2025.102316_bib0002","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00345-006-0123-x","article-title":"Chemoprevention of bladder cancer","volume":"24","author":"Golijanin","year":"2006","journal-title":"World J. Urol."},{"key":"10.1016\/j.clgc.2025.102316_bib0003","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","article-title":"The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incid and mortality risks","volume":"70","author":"Cumberbatch","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clgc.2025.102316_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccr.2004.08.002","article-title":"Focus on bladder cancer","volume":"6","author":"Dinney","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2025.102316_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clgc.2025.102316_bib0006","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clgc.2025.102316_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.clgc.2025.102316_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clgc.2025.102316_bib0009","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u2018unfit\u2019 for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.clgc.2025.102316_bib0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102316_bib0011","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.clgc.2025.102316_bib0012","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.3390\/ijms22137201","article-title":"Perioperative systemic treatment for muscle-invasive bladder cancer: current evidence and future perspectives","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.clgc.2025.102316_bib0013","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.clgc.2025.102316_bib0014","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.clgc.2025.102316_bib0015","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.clgc.2025.102316_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19535","article-title":"Association Between Food and Drug Administration Approval and disparities in immunotherapy use among patients with cancer in the US","volume":"5","author":"Ermer","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.clgc.2025.102316_bib0017","doi-asserted-by":"crossref","first-page":"e19364","DOI":"10.1200\/JCO.2020.38.15_suppl.e19364","article-title":"The value of immunotherapy: comparison of annual cost per patient receiving immunotherapy versus chemotherapy in patients with non-small cell lung cancer","volume":"38","author":"Vasekar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clgc.2025.102316_bib0018","doi-asserted-by":"crossref","first-page":"732.e9","DOI":"10.1016\/j.urolonc.2021.03.004","article-title":"Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer","volume":"39","author":"Khaki","year":"2021","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.clgc.2025.102316_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s40425-019-0782-y","article-title":"Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma","volume":"7","author":"Krimphove","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.clgc.2025.102316_bib0020","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.3390\/curroncol31050192","article-title":"Income disparities in survival and receipt of neoadjuvant chemotherapy and pelvic lymph node dissection for muscle-invasive bladder cancer","volume":"31","author":"Antar","year":"2024","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"10.1016\/j.clgc.2025.102316_bib0021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.euo.2023.06.005","article-title":"Downstaging and survival associated with neoadjuvant immunotherapy before radical cystectomy for muscle-invasive bladder cancer","volume":"7","author":"Grassauer","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.clgc.2025.102316_bib0022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2023.41.6_suppl.531","article-title":"Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): a systematic review and meta-analysis","volume":"41","author":"Ayaz","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:25:19Z","timestamp":1754551519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000175"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102316","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Neoadjuvant Immunotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer in a National Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102316"}}